BL(SZ:002592)2021-04-29 16:00Financial Performance - The company's operating revenue for Q1 2021 was ¥157,023,547.17, representing an increase of 18.31% compared to ¥132,722,227.89 in the same period last year[7]. - Net profit attributable to shareholders was ¥166,370,343.18, a significant increase of 2,215.32% from a loss of ¥7,865,024.63 in the previous year[7]. - The net profit after deducting non-recurring gains and losses was ¥12,624,302.28, up 214.60% from a loss of ¥11,015,881.98 in the same period last year[7]. - The basic earnings per share rose to ¥0.63, compared to a loss of ¥0.03 per share in the same period last year, marking a 2,200.00% increase[7]. - The company reported a net loss of CNY 473,015,960.62, an improvement from a loss of CNY 639,386,303.80 in the previous period[63]. - The company reported a total comprehensive income of CNY 165,282,853.15 for Q1 2021, compared to a loss of CNY 10,666,956.24 in the previous year[71]. - The net profit for the first quarter of 2021 was CNY 165,591,041.58, a significant increase compared to a net loss of CNY 5,393,569.19 in the same period last year[74]. - Operating profit reached CNY 191,780,326.28, compared to an operating loss of CNY 5,956,905.30 in the previous year, indicating a strong turnaround in performance[74]. Assets and Liabilities - The total assets at the end of the reporting period were ¥1,515,986,459.31, an increase of 3.26% from ¥1,468,131,594.46 at the end of the previous year[7]. - The total liabilities decreased to CNY 590,994,785.08 from CNY 698,446,528.38, a decrease of approximately 15.4%[62]. - Owner's equity increased to CNY 924,991,674.23 from CNY 769,685,066.08, reflecting an increase of about 20.2%[63]. - Total assets increased to CNY 1,515,986,459.31 as of March 31, 2021, up from CNY 1,468,131,594.46 at the end of 2020, representing a growth of approximately 3.6%[61]. - Current assets totaled CNY 641,961,751.65, an increase from CNY 586,537,521.93, reflecting a rise of about 9.4%[60]. - Total liabilities decreased to CNY 582,107,034.35 from CNY 676,092,820.01 year-over-year[69]. Cash Flow - The company reported a net cash flow from operating activities of -¥10,357,163.96, a decline of 839.02% compared to ¥1,401,466.65 in the same period last year[7]. - The cash flow from operating activities showed a net outflow of CNY 10,357,163.96, contrasting with a net inflow of CNY 1,401,466.65 in the same quarter last year[78]. - The cash flow from investing activities generated a net inflow of CNY 79,224,604.63, compared to CNY 168,187,979.60 in the same period last year[78]. - The cash flow from financing activities resulted in a net outflow of CNY 72,384,778.51, compared to a net outflow of CNY 31,268,354.65 in the previous year[79]. Share Repurchase and Equity - The company plans to repurchase shares using between 100 million and 300 million CNY of its own funds at a price not exceeding 16.35 CNY per share[37]. - As of December 19, 2018, the company repurchased a total of 16,826,900 shares, accounting for 5.94% of the total share capital, with an average purchase price of 12.58 CNY per share[38]. - The total amount spent on the share repurchase was 211,609,144 CNY, excluding transaction fees[38]. - The company’s share repurchase plan is aimed at supporting employee stock ownership and equity incentives[42]. - The repurchased shares will not impact the company's operating performance for the year 2021 but will affect the capital reserve[40]. Legal and Regulatory Matters - The company is under investigation by the China Securities Regulatory Commission for suspected violations of information disclosure laws, which may lead to administrative penalties and the risk of stock delisting[33]. - The company is pursuing legal actions to recover 296 million CNY of misappropriated funds and has taken measures to ensure the return of all occupied funds[32]. - Wang Anxiang has committed to repay all funds occupied and pay an annualized interest of 10%, but as of the announcement date, the funds have not been returned[48]. Operational Developments - The company is in the process of disposing of 51% equity in its subsidiary Beijing Hongrun Tianyuan Gene Biotechnology Co., Ltd. to reduce operational risks and prevent further losses[28]. - The company is actively expanding its market presence and exploring new strategies for growth, as indicated in various announcements throughout early 2021[36]. - The automotive parts business has gradually returned to normal levels as the domestic automotive market recovers with the improving pandemic situation[51].